Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
Open accessThe DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; none of the 86 sources its claims cite is checked for support yet.
Abstract
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence.
Overview
CoChat Summary
## TL;DR
This review argues that poor medication adherence in type 2 diabetes is common, often affecting at least half of patients, and is tied to worse glycemic control, higher costs, and higher mortality. It highlights two broad modifiable drivers: treatment burden and patients’ treatment-related beliefs.
## Key findings
- Reported poor medication adherence in T2D ranged from 38% to 93% across studies, largely because definitions and methods varied; using MPR ≥80%, adherence was 47.3% for dipeptidyl peptidase-4 inhibitors, 41.2% for sulfonylureas, and 36.7% for thiazolidinediones in a 238,000-patient MarketScan analysis.
- Poor adherence was associated with worse outcomes: among >11,000 veterans, MPR <80% was significantly associated with poor glycemic control (HbA1c >8%, P<0.001); in 1,198 survey respondents, each 1-point drop in self-reported adherence was linked to a 0.21% increase in HbA1c and increases of 4.6%, 20.4%, and 20.9% in physician, ER, and hospital visits.
- Mortality was higher with poor adherence: in 15,984 UK patients, poor adherence and missed visits were each associated with a 1.6-fold increase in all-cause mortality (P<0.001); another study reported an odds ratio of 1.8 (P<0.001).
- Economic impact was substantial: improved adherence was projected to reduce hospitalization/ER risk by 13%, worsening adherence to raise it by 15%, and one analysis estimated annual savings of $4.7 billion with improved adherence and $3.6 billion with reduced poor adherence.
## Methods
- Narrative review of the literature on medication adherence in T2D, focusing on the scope of the problem, consequences, key contributors, interventions, and future developments.
- The paper synthesizes findings from retrospective/observational claim-database studies, surveys, and meta-analyses; it cites examples including analyses of 238,000 MarketScan patients, >11,000 veterans, 1,198 survey respondents, and other large database studies.
- Main analysis is qualitative synthesis of reported adherence rates, outcomes, and modifiable contributors, with attention to common adherence metrics such as medication possession ratio (MPR) ≥80% and persistence definitions.
## Limitations
- The paper states that much of the evidence comes from retrospective or observational claim-database studies using widely varying definitions, making findings difficult to interpret.
- It states that intervention evidence is limited because adherence measures vary widely, hard outcomes are often lacking, interventions are not clearly explained, and follow-up is often inadequate.
- Evident from the text: this is a review, not a new primary study, so its conclusions depend on the quality and comparability of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 57 Not checked · 17 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In one study that tracked new prescriptions written electronically over a 12-month period for >75,000 patients, 31.4% of new prescriptions for diabetes drugs were never filled.25”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Scope of the problem
What the sources say
- Not matchedcites [25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainn = 75,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia)”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 75 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from this survey highlight patient perspectives on reasons for treatment discontinuation among people with T2DM in the USA and UK and provide focal points for communication for these individuals when they are initiating new therapies [5].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the NICE guidance (NG28) and gastrointestinal tolerability are likely important drivers, early GLP‐1RA discontinuation is plausibly multifactorial and may also reflect perceived treatment effectiveness, complex dosing schedules, injection‐related barriers, limited access to diabetes education, economic constraints, and medication shortages. 19 , 32 , 33 , 34”
From Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Up to 50% of people with T2DM discontinue treatment by 1 year [5].”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 2×
“65 A key element is the need for greater consistency when measuring medication adherence, which require better instruments and tools for assessment.”
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“Even worse, it has been well documented that this cost burden has been inexorably growing worldwide.(10) A key contributor to the remarkably high rates of morbidity and mortality is chronic poor metabolic control, especially poor glycemic control.”
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“41 In their comprehensive review of 76 studies, Claxton et al 42 found that the prescribed number of doses per day was inversely associated with medication adherence; indeed, the mean adherence across studies decreased progressively from 79% with a once-daily dose to 51% with a four times daily…”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationPrimary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions
Fischer, M. A., Stedman, M. R., Lii, J., Vogeli, C., Shrank, W. H., Brookhart, M. A., & Weissman, J. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1253-9 · Cited by 572 · cited 1×
“25 This problem, often referred to as primary nonadherence, may be particularly relevant among patients who are refusing to initiate insulin or other injectable hypoglycemic therapy, typically due to injection phobia, inconvenience, poor patient–physician communication, and/or negative patient…”
Cited by
Items 501–600 of 761
The fundamentals of diabetes care
Gordon, C., & Hill, B. (2024) · British Journal of Nursing · doi:10.12968/bjon.2024.0300 · Cited by 10
Vasa, D., Guerra, L., Goel, M. S., Harris, Y., & Lin, J. J. (2024) · Psycho-Oncology · doi:10.1002/pon.9309 · Cited by 2
“Previous studies have demonstrated a multitude of factors associated with DM treatment non-adherence in non‐cancer populations, including treatment cost, complexity, and convenience as well as medication beliefs and perceived treatment efficacy [23].”
Six, S., Israel, D., Bilsen, J. J. R., & Kharagjitsing, A. V. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310800 · Cited by 3
Out-of-Pocket Costs Burden in Marketplace Plans for People With Diabetes
Ruscitti, B., Kern, C., & H, D. B. M. P. (2024) · Health Services Insights · doi:10.1177/11786329241304618 · Cited by 3
Wahiduzzaman, M., Islam, M. S., Hossain, S., & Islam, S. M. S. (2025) · Preventive Medicine Research & Reviews · doi:10.4103/pmrr.pmrr_216_24 · Cited by 3
Chen, C., Hsu, S., & Chien, L. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112216 · Cited by 2
Prescribing Antidiabetic Medications Among GPs in Croatia—A Real-Life Cross-Sectional Study
Kurevija, T., Schönberger, E., Ličanin, M. M., Bilić-Čurčić, I., Majnarić, L. T., & Canecki-Varžić, S. (2025) · Biomedicines · doi:10.3390/biomedicines13061491 · Cited by 2
Kepatuhan Pengobatan Pada Penderita Diabetes Melitus Tipe 2 Di Puskesmas X Kota Malang
Supriyadi, S., Dewi, N., & Ridja, E. W. (2021) · Nursing News Jurnal Ilmiah Keperawatan · doi:10.33366/nn.v5i1.2267 · Cited by 2
What drives glycemic control in a person living with diabetes?
Singla, R., Gupta, G., & Gupta, Y. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00979-9 · Cited by 2
Technique d’injection de l’insuline : que font les patients diabétiques en France ?
Sauvanet, J.-P., & Halimi, S. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30098-6 · Cited by 4
Finding Joe: Patient-directed goal setting on the journey to therapeutic targets in diabetes care
Krejany, C., & Jiwa, M. (2019) · The Journal of Health Design · doi:10.21853/jhd.2018.80 · Cited by 2
“Programs to improve patients’ health literacy, interventions to increase review and screening attendance rates, changes to doctors’ information delivery, cultural competency, setting, and social context, have all been suggested.(3,12,13) Effectively, doctors need to say it better and patients need to be taught how to…”
BackgroundSwamynathan, M., & Sivasubramanian, P. (2020) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20202494 · Cited by 2
“Prevalence of good treatment adherence was 39% in a hospital based study conducted at Tamil Nadu.29 Treatment adherence was directly related to prevention of complications and hence prevention of mortality and morbidity due to DM.30,31 Studies done at various parts of world had suggested that untreated anxiety and/ or…”
BackgroundKauppila, T., Laine, M. K., Honkasalo, M., Raina, M., & Eriksson, J. G. (2020) · International Journal of Circumpolar Health · doi:10.1080/22423982.2020.1773127 · Cited by 2
Widjaja, S. S., Rusdiana, R., Savira, M., & Amelia, R. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.6520 · Cited by 2
Grundlagen des Diabetesmanagements
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1590-7867 · Cited by 2
Hussain, S. A., Al-Tukmagi, H., Abdulrahman, Z. S., SADEQ, M. M., HASHİM, D. N., KADHİM, R. S., Kubba, M. M., & Tukmagi, D. A. (2021) · Istanbul Journal of Pharmacy · doi:10.26650/istanbuljpharm.2021.870571 · Cited by 3
Mosleh, R., U’wais, A., Hamdan, A., Ghanim, M. A., & Jarrar, Y. B. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220523114806 · Cited by 5
Insulin Therapy in Type 2 Diabetes Mellitus
(2022) · The Singapore Family Physician · doi:10.33591/sfp.48.1.u2 · Cited by 2
Rao, D., Stevenson, B., & Shiyanbola, O. O. (2023) · Ethnicity and Health · doi:10.1080/13557858.2023.2198683 · Cited by 7
Study of adherence to treatment of patients with diabetes in Ukraine.
Власенко, І. О. (2023) · Farmatsevtychnyi zhurnal · doi:10.32352/0367-3057.4.23.04 · Cited by 2
Bromocriptine and Colesevelam Hydrochloride: Novel Therapies for Type II Diabetes Mellitus
Soileau, L. G., Nguyen, A., Senthil, A., Boullion, J. A., Talbot, N. C., Ahmadzadeh, S., Shekoohi, S., Kaye, A. D., & Varrassi, G. (2023) · Cureus · doi:10.7759/cureus.50138 · Cited by 5
“It has been reported that at least 45% of patients prescribed pharmaceutical therapies fail to achieve adequate glycemic control due to poor medication adherence [21].”
BackgroundGolembiewski, E. H., Bautista, A. E. G., Polley, E. C., Umpierrez, G. E., Galindo, R. J., Brito, J. P., Montori, V. M., Gockerman, J. P., Tesulov, M., Labatte, B., et al. (2024) · Clinical Diabetes · doi:10.2337/cd23-0042 · Cited by 2
Hope, C. O., Agnes, N. A., Chinenye, J. A., et al. (2020) · Journal of Diabetes and Endocrinology · doi:10.5897/jde2019.0133 · Cited by 2
Matha, K., Calvignac, B., Gangneux, J., & Benoît, J. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1853701 · Cited by 2
Sinamaw, D., Belay, D. G., Chilot, D., Gela, Y. Y., Diress, M., Seid, A. M., Simegn, W., Kibret, A. A., Eshetu, H. B., Bitew, D. A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2013068/v1 · Cited by 2
Living with diabetes : managing treatment and the psycho-social aspects of the disease
Ramraj, U. (2023) · DUT Open Scholar (Durban University of Technology) · doi:10.51415/10321/4923 · Cited by 4
VISENTIN, R., Cobelli, C., Sieber, J., & Man, C. D. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231223936 · Cited by 2
Management of patients with type 2 diabetes mellitus in the Grand-Aides Program
Compton, R. M., Bednar, K. S., Donowitz, P. E., et al. (2019) · Journal of Nursing Education and Practice · doi:10.5430/jnep.v10n3p1 · Cited by 1
Abitbol, A., Siemens, R. L., Nightingale, N., Stewart, J. A., Toutounji, M.-J., & Goldenberg, R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108920 · Cited by 2
Determination of Risk Factors for the Development of Diabetic Foot Disease
Isil, G., & Demirci, H. (2021) · European Journal of Human Health · doi:10.29228/ejhh.52419 · Cited by 1
Shimels, T., Abebaw, M., & Gebretekle, G. B. (2021) · Journal of Social Health and Diabetes · doi:10.1055/s-0041-1732783 · Cited by 1
Kaneto, H., Baxter, M., Takahashi, Y., & Terauchi, Y. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02311-1 · Cited by 1
“While the relationship between treatment compliance and treatment outcomes in patients with T2D is well established [27], the importance of compliance in the first 6 months is not well studied, and further investigation is required to better characterize the clinical outcomes in patients with good early compliance.”
BackgroundEsquivel-Prados, E., Battikh, H. R., & Corpas, J. P. G. (2023) · Ars Pharmaceutica (Internet) · doi:10.30827/ars.v65i1.29147 · Cited by 2
Alomar, O., & Rabbani, U. (2024) · Cureus · doi:10.7759/cureus.55345 · Cited by 1
BÜYÜKBAYRAM, Z., & Aydın, L. Z. (2024) · Artuklu Health · doi:10.58252/artukluhealth.1475124 · Cited by 1
“In a similar study, the findings displayed that patients showed low adherence to treatment (Polonsky & Henry, 2016).”
ResultAlharbi, S., Alhofaian, A., & Alaamri, M. M. (2024) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_511_23 · Cited by 1
“[10] Furthermore, factors such as perceived inefficacy of treatment, the complexity of treatment regimens, the risk of hypoglycemia, and the burden of medical expenses have been identified as key contributors to non‑adherence.”
BackgroundHerbal Remedies for Type 2 Diabetes Mellitus: An Explicit Review
Grover, R., Mittal, V., & Sharma, A. (2024) · Current Drug Therapy · doi:10.2174/0115748855307512240802043813 · Cited by 4
Harvey, I. S., Mkuu, R. S., Thompson, R., Nouzovsky, A., Johnson, K., Story, C. R., Seals, K., Idoko, E., & Wiggins, A. (2024) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106241289098 · Cited by 1
Ajeetha, B., Ade, A. D., Guthi, V. R., & Meesala, L. (2025) · National Journal of Community Medicine · doi:10.55489/njcm.160120254691 · Cited by 1
Masudo, C., Horii, T., Suzuki, R., & Mihara, K. (2025) · Cureus · doi:10.7759/cureus.80511 · Cited by 1
Zhang, B., Powwattana, A., Sillabutra, J., Liu, G., Li, S., & Kalampakorn, S. (2025) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106251319541 · Cited by 1
“32 Based on these findings, health care providers should prioritize enhancing medication awareness and emphasizing its benefits for the preaction stage to support patients taking medication.”
Zhang, P., Mason, J. E., Sohn, M., Balkrishnan, R., Anderson, R. T., McCall, A. L., & Kang, H. (2025) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-025-02388-8 · Cited by 1
Nguyen, M., Bùi, T. B. H., Huynh, T. T., & Nguyen, Q.-V. (2025) · Food Research International · doi:10.1016/j.foodres.2025.116587 · Cited by 1
Nurkolis, F., Romano, R., & Santini, A. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01755-z · Cited by 1
“Despite progress in pharmacological and lifestyle interventions, current therapies fall short of addressing the root causes of DM and often carry side effects that impair adherence [11].”
Ashraf, T., Kumar, A., Tara, A., Memon, N., Muhammad, A., Turesh, M., Dev, S., Muhammad, N., Kumar, V., Hussain, T., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003392 · Cited by 2
“It affects 6.28% of the global population (approximately 462 million people), and its prevalence is expected to exceed 1.3 billion cases in the next 30 years [ 2 , 3 ] .”
InfluentialUtomo, W. B., Muzdalipah, Muhajir, R. A., & Fawzi, Y. (2025) · INTERNATIONAL JOURNAL OF NURSING AND MIDWIFERY SCIENCE (IJNMS) · doi:10.29082/ijnms/2025/vol9/iss1/703 · Cited by 1
Ahiale, C., & Kumah, A. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1604828 · Cited by 2
“This helps in the timely detection of fl uctuations and allows for appropriate adjustments in treatment plans (19).”
InfluentialWahyuni, A. S., MARWA, D., OKTASARI, S. R., Yulianti, T. E., Nugraheni, A. Y., & AL-SAMEA, R. A. M. O. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025.v17s2.20 · Cited by 2
Škop, V., Laňková, I., Antalová, S., Míšková, I., Malá‐Ládová, K., Malý, J., Pelikánová, T., Hričko, J., Čajka, T., & Haluzík, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70174 · Cited by 3
“While previous studies have examined the extent of non-adherence, 4,6 its underlying causes remain incompletely understood.”
Almadfaa, R. O. (2025) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2025.10.013 · Cited by 2
PINTO, O. S., SHETTY, R., FAIZAL, U. Y. F., et al. (2025) · International Journal of Current Pharmaceutical Research · doi:10.22159/ijcpr.2025v17i6.8004 · Cited by 1
Wernersson, A. S., Akhtar, S., Frøhling, K. B., & Sparre, T. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251395041 · Cited by 2
Gonzalez, J. S., Wen, H., BUTERA, N. M., Uschner, D., Krause-Steinrauf, H. J., Gramzinski, M. R., Wexler, D. J., Petrovitch, H., Hoogendoorn, C. J., Crespo-Ramos, G., et al. (2026) · Diabetes Care · doi:10.2337/dc25-2008 · Cited by 3
Hood, K. K., & Polonsky, W. H. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251403584 · Cited by 1
Self-citationZhou, J., Lee, D. A., Talebi, Y., Wu, G., & Wu, H. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.02.003 · Cited by 1
Milushewa, P., Chenesheva, N., & Petkova, V. B. (2026) · Pharmacy · doi:10.3390/pharmacy14010035 · Cited by 1
“Suboptimal adherence is associated with poor glycemic control, increased complication risk, and higher healthcare costs [8].”
Basu, S., Sengupta, T., & Kundu, S. (2026) · Health Science Reports · doi:10.1002/hsr2.71845 · Cited by 5
Ali, D., Bilal, A. R., Arfin, S. M. W., Sajid, M., Qureshi, S., Ahmed, R., Aminpoor, H., & Waqas, S. A. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70178 · Cited by 2
Aloudah, N. M. (2026) · Patient Preference and Adherence · doi:10.2147/ppa.s603658 · Cited by 1
“1 Although medication adherence is widely recognised as a multidimensional behaviour, its assessment in both research and routine clinical practice has often relied on tools that primarily quantify medication-taking behaviour, such as missed doses or prescription refills.”
Gandhi, P. B., Jacob, Y., MacField, J. F., Merlo, G., Meyer, S. M., Patel, S., Rhéaume, C., Staffier, K. L., Watson, M., & Karlsen, M. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072524 · Cited by 1
“…more complex regimens can lead to worse HbA1c outcomes due to factors such as the complexity of treatment and side effects such as hypo-glycemia, and nonadherence to these medications is high, close to 50%, which can lead to poor glycemic control and raise the overall risk for mortality [6,7].”
Jacob, Y., Staffier, K. L., Menon, S., Gandhi, P. B., MacField, J. F., Merlo, G., Meyer, S. M., Patel, S., Rhéaume, C., Watson, M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072561 · Cited by 1
“While glucose-lowering medications remain central to T2D management, reliance on pharmacotherapy does not treat the root cause of the disease and can lead to side effects, treatment burden, and increased healthcare costs [3–8].”
Fenwick, E., Man, R. E. K., Ho, A. X. Y., Lee, E. P., Tai, E. S., Tan, N. C., Toh, S.-A. E. S., Tham, T. Y., Khoo, C. M., Bee, Y. M., et al. (2026) · Advances in Patient-Reported Outcomes · doi:10.1016/j.apro.2026.100329 · Cited by 1
Ji, L., Gao, L., Dong, R., Yuan, M., Zhao, D., Pang, S., Zhao, J., Zhao, L., & Chen, W. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102743 · Cited by 2
Anasobi, R. T., Stewart, O., & Stumbris, R. (2026) · Cureus · doi:10.7759/cureus.108555 · Cited by 1
“Medication nonadherence was identified clinically as a likely contributor to poor glycemic control [10].”
Holle, A. F. V., Mohl, J. T., Zuckerman, R. B., Obenrader, J., & Ciemins, E. L. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.7.793 · Cited by 1
Liu, M. R., Cheng, Z. F., Li, L., Cai, H., Liu, J., Liu, J., Zheng, Y., Wang, S., Zhao, J., Yang, W., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-04623 · Cited by 1
Translating diabetes research from multiple directions – microvascular to psychosocial
Olson, D. E. (2017) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2017.08.002 · Cited by 1
Marjanović, M., Lang, V. B., & Đido, V. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.02.009 · Cited by 1
Nair, P., Kee, K. W., Mah, C. S., & Lee, E. S. (2020) · Journal of Primary Care & Community Health · doi:10.1177/2150132720965085 · Cited by 1
“916 Median number of HTN medications (IQR) 2 (1-3) 2 (2-3) .”
BackgroundA1C Reduction in Patients Who Declined Pharmacist-Led Diabetes Management Services
Ahmed, F., Hammad, S., Lin, J., Gennaro, T. L., Gaspard, A. L., Sarpong, D. F., & Onor, I. O. (2021) · Journal of Pharmacy Practice · doi:10.1177/0897190021993390 · Cited by 1
“Research has shown that there is an association between patients’ trust in healthcare professionals and their medication adherence, and refusal of these programs may be related to the perceived care they would receive.(9) Disease state management programs that assessed overall quality of life and patient well-being fo…”
BackgroundRELUCTANCE OF PATIENTS WITH DIABETES MELLITUS TO INSULIN THERAPY; PSYCHOLOGICAL INSULIN RESISTANCE
Ali, U., Munir, M. W., Maqsood, J., et al. (2021) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v71i2.4137 · Cited by 1
Fundamentals of Diabetes Management
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-5080 · Cited by 1
“This is particularly true for diabetes, which often involves polypharmacy with changing dosages, times of intake, side effects and interactions, and where the implementation of dietary and exercise regimens is often poor [22].”
BackgroundLaila Afifah, A. B., Lestari, F., & Mulqie, L. (2022) · Bandung Conference Series Pharmacy · doi:10.29313/bcsp.v2i2.4841 · Cited by 1
Pradhyta, F. P., Sartika, R. A. D., & Sauriasari, R. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666221130104225 · Cited by 1
The Affecting Factors of Compliance Diabetes Mellitus Type 2 Treatment in Pandemic Era
Febrinasari, R. P., Solikah, T. A., Pakha, D. N., et al. (2022) · Jurnal Kesehatan Masyarakat · doi:10.15294/kemas.v17i4.29885 · Cited by 1
Factors Influencing Adherence to Anti-Diabetes Medication Among Diabetes In Accra
Milla-Amekor, E. (2023) · Central European Management Journal · doi:10.57030/23364890.cemj.31.1.72 · Cited by 1
Ewusie, E. M.-A. A. E. A. (2023) · Central European Management Journal · doi:10.57030/23364890.cemj.31.1.73 · Cited by 1
Subba Krishna, N., Sharma, S., Lahiri, A., Sai, M., Kesri, S., Pakhare, A. P., Kokane, A. M., Joshi, R. P., & Joshi, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230427094530 · Cited by 1
Ouchi, D., Vilaplana-Carnerero, C., Monfà, R., Giner‐Soriano, M., García-Sangenís, A., Torres, F., & Morros, R. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00374-2 · Cited by 1
“Despite the availability of many classes of medication in the DM2 field, medication adherence is poor [17].”
BackgroundDavidson, M. B., Davidson, S. J., & Duran, P. A. (2023) · Clinical Diabetes · doi:10.2337/cd23-0066 · Cited by 2
Aldekheel, S. K. S., & Shahin, M. A. H. (2024) · Diabetes Mellitus · doi:10.14341/dm13112 · Cited by 2
Tackling the burden of chronic ill health in emergency medicine
Mason, S. J., Lewis, J., & Wren, J. (2024) · Canadian Journal of Emergency Medicine · doi:10.1007/s43678-024-00721-4 · Cited by 1
“As this study identifies, these are often harder to reach groups who tend to default on appointments, find access to care more difficult and struggle to adhere to treatment regimes [5].”
Kanny, S., Cummings, W. H., Carbajales‐Dale, P., et al. (2024) · Preventing Chronic Disease · doi:10.5888/pcd21.240068 · Cited by 1
Kim, N. H., Moon, J. S., Ha, K. H., Kim, J., Kwon, K.-E., Kim, S. G., & Kim, D. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112405 · Cited by 4
Subramanian, D. A., Kirtane, A. R., White, G. N., Freitas, D. E., Ishida, K., Jenkins, J. A., Pettinari, A., Morimoto, J., Fitzgerald, N. J., & Traverso, G. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123889 · Cited by 2
Malcolm, M. P., Atler, K. E., Schmid, A. A., Klinedinst, T. C., Swink, L. A., Marchant, T. P., & Marchant, D. R. (2018) · Clinical Diabetes · doi:10.2337/cd17-0118 · Cited by 3
Insulin Therapy in Type 2 Diabetes Mellitus
Tan, H. H., & Sum, C. F. (2019) · The Singapore Family Physician · doi:10.33591/sfp.45.2.u2 · Cited by 1
Gusti, E. K. M., Kuswinarti, K., & Dahlan, A. (2020) · JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) · doi:10.22146/jmpf.51856 · Cited by 1
Diabetes: Biopsychosocial Features Affecting Metabolic Control and Treatment Adherence
Miller, F. G., Anderson, M., Tucker, D. R., Vaz, K., Brown, J. G., Anderson-Jackson, L., & McGrowder, D. A. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-2139-7.ch007 · Cited by 1
Anderson, J. E., Urquhart, S., Spollett, G. R., & Dandona, P. (2020) · Clinical Diabetes · doi:10.2337/cd20-0035 · Cited by 1
Life Experiences of Javanese Women with Type-2 Diabetes Mellitus
Rayanti, R. E., & Saputri, A. (2020) · International Conference on Gender Equality and Ecological Justice (GE2J) · doi:10.4108/eai.10-7-2019.2299666 · Cited by 2
“Factors related to poor medication adherence of diabetes patients are lower education levels, and lower incomes[18].”
BackgroundAn assessment of physician reasons for prescribing Insulin Lispro 200 units/ml in Germany
Chen, J., Perez‐Nieves, M., de Oliveira, C. P., Spaepen, E., Osumili, B., Poon, J. L., Schloot, N. C., Lara, N., Alvarez, L. G., & Roset, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1805968 · Cited by 1
Osmotic controlled drug delivery system (OSMO technology) and its impact on diabetes care
Rajput, R., Kumar, K. M. K. P., Arya, D. S., Das, A. K., Zargar, A. H., TIWASKAR, M. H., Motghare, V. M., Shah, R. D., INGOLE, S. A., & Jain, R. (2020) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20205861 · Cited by 1
Rosenstock, J., Blonde, L., Aroda, V. R., Frías, J. P., Souhami, E., Ji, C. F., Niemoeller, E., & Prato, S. D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14345 · Cited by 1
“Simplification of treatment regimens in people with T2D has been shown to offer medication adherence benefits.(3) Fixed-ratio combinations (FRCs) of a basal insulin and a GLP-1 RA enable administration of both therapies simultaneously, and thereby reduce the number of injections required per day compared with administ…”
BackgroundAddressing Nutritional Gaps: Simple Steps for the Primary Care Provider
Quan, Q. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0059 · Cited by 1
Peter, N. K., Norman, S. R., Mahima, M., Fikry, I., Anne, N. M., Shurney, D. W., Kieschnick, D. W., & Cerrone, K. L. (2020) · doi:10.36959/784/422 · Cited by 1
An Individualized, Case-Based Approach to the Management of Irritable Bowel Syndrome
Lacy (2020) · The Journal of Family Practice · doi:10.12788/jfp.0060 · Cited by 1
Formulation Designing Factors for Development of Repaglinide Transdermal Therapeutic System
Pethani, D. K., & Prajapati, S. T. (2020) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2020.120209 · Cited by 1
“6 % of the patients were considered adherent to the prescribed anti-diabetic drugs.[3] Article history:”
BackgroundChandran, K., Tai, K. P., Toh, M. P. H. S., Phng, F. W. L., Seah, E.-J. D., & Wu, C. X. (2019) · Journal of Endocrinology and Metabolism · doi:10.14740/jem563 · Cited by 1
Drug Related Problems Diabetic Nephropathy Patients in a Tertiary Hospital in Malaysia
Destiani, D. P., & Ghazali, A. (2016) · Pharmacology and Clinical Pharmacy Research · doi:10.15416/pcpr.v1i2.15207 · Cited by 1
Metadata
- Authors
- Polonsky, W., & Henry, R.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Polonsky, William
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- Volume 10
- Pages
- 1299-1307
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC4966497
- OpenAlex
- W2493860075
- Cited by
- 784
- References
- 77
- Citations by year
- 2026: 93 · 2025: 97 · 2024: 89 · 2023: 82 · 2022: 108 · 2021: 106 · 2020: 106 · 2019: 54 · 2018: 34 · 2017: 13 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- medication adherence, type 2 diabetes, glycemic control, barriers to adherence, medication beliefs, medication burden, out-of-pocket costs, hypoglycemia, treatment complexity, clinical inertia, socioeconomic factors, diabetes complications, drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.